Research library
Other NotablePlausible but unproven in humans
HGH Fragment 176-191
AOD-9604, GH lipolytic fragment
A modified C terminal fragment of growth hormone (176-191) intended to isolate GH's fat burning action without raising IGF-1 or affecting blood glucose.
hGH 176-191
β3-adrenergic
Failed Ph IIb
How AOD-9604 works
A growth hormone fragment meant to keep GH's fat burning effect while dropping its growth and blood sugar effects. The catch: it failed its pivotal human obesity trial.
AOD-9604
β3-adrenergic
Lipolysis
No IGF-1 rise
Research applications
Obesity / fat loss
Marketed use
Lipolysis
Mechanism
Bars indicate how far the evidence has progressed (in vitro to animal to human), not the size of any effect.
Molecular profile
Evidence, safety & status
Claimed benefits & evidence
Marketed as a fat loss peptide. A 12-week trial (300 obese adults) showed 1 mg/day produced ~2.6 kg loss vs 0.8 kg placebo, but the pivotal Phase IIb trial failed to reach statistical significance and development for obesity was abandoned in 2007; six trials (~900 subjects) showed safety indistinguishable from placebo but inconsistent efficacy.
Safety & dangers
Reassuring safety in trials, no IGF-1/glucose changes, no anti AOD antibodies, headache/mild GI comparable to placebo. The main 'danger' is the gray market and ineffectiveness for the marketed purpose.
Regulatory status
Not FDA approved; FDA lists it as a bulk substance that may present safety risks. Category 2 (2023); PCAC voted against 503A inclusion (Dec 2024). WADA prohibited (S2, AOD-9604 and hGH 176-191 named).
Administration
Subcutaneous (oral was also trialed).
Source: Fnx Performance Peptide Research Database, a synthesis of the scientific and regulatory literature, not medical advice. For medical questions, consult a qualified physician.
For research use only
For Research Use Only. Not for human or animal consumption. Products are sold strictly for in vitro laboratory research, not for compounding or therapeutic application.